Stem cells and hypertension: what Cheongdam Cell Clinic states

Hypertension is one of the age-related conditions Cheongdam Cell Clinic lists on its 淸(Rejuvenation)CELL programme page, where the clinic's own wording states the therapy has been 'proven to prevent and treat' such conditions. This article presents that as a claim the clinic makes, not as a medical conclusion verified by large, publicly available trials — readers should weigh it with that evidence limitation in mind.

The underlying rationale is that hypertension is partly linked to age-related arterial stiffness — the hardening and loss of elasticity in blood-vessel walls. The clinic explains that intravenously injected stem cells play a role in 'regenerating the blood vessels', a proposed mechanism used to explain why this programme is grouped alongside care for other cardiovascular conditions.

In mainstream medicine, hypertension is a chronic condition well managed with antihypertensive drugs, sodium restriction, exercise, weight management and smoking cessation. Human research on stem cells and blood pressure remains mostly early-stage or small in scale, and no major international treatment guideline currently recognises it as a primary or replacement therapy for medication.

Cheongdam Cell Clinic uses the patient's own (autologous) bone-marrow stem cells with no cell-culture step; harvesting, isolation and intravenous injection are completed within a single half-day. The clinic states patients can return to normal daily life from the day of the procedure — a point it uses to communicate the programme's convenience.

Thai patients with hypertension considering this programme should disclose their antihypertensive medication history, comorbidities such as diabetes or kidney disease, and recent blood test results to the clinic's doctors before deciding, so suitability and procedure safety can be properly assessed. It is also worth asking the clinic directly what specific outcomes it observes for blood pressure in practice.

It is important not to stop antihypertensive medication independently simply because a stem-cell programme is planned. Poorly controlled hypertension raises the risk of heart disease, stroke and kidney disease. Any medication changes should be made under the guidance of the physician managing the underlying condition, not decided unilaterally based on any single clinic's marketing material.

The 淸(Rejuvenation)CELL programme is positioned by the clinic as broader anti-ageing and immune-system support rather than a specialised, direct treatment for hypertension. Prospective patients should calibrate expectations accordingly and view it as a supplementary part of long-term health care, not a primary treatment.

Before travelling to Seoul for this programme, request written documentation from the clinic about the procedure, risks and cost, since the clinic does not publish prices publicly — every case requires an individual quote. Patients should also always consult their regular physician in Thailand in parallel.